Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL190490 | 1.00 | CA1 (0.33) | CA1CA2ACHECA12CA9 | |
| SCHEMBL13696645 | 1.00 | CA1 (0.33) | CA1CA2ACHECA12CA9 | |
| SCHEMBL12166804 | 1.00 | CA1 (0.33) | CA1CA2ACHECA12CA9 | |
| SCHEMBL191513 | 0.97 | ACHE (0.30) | ACHE | |
| Methane SCHEMBL29077722 | 0.94 | CYP19A1 (0.32) | CYP19A1NPC1 | |
| SCHEMBL2696797 | 0.91 | — | — | |
| SCHEMBL22959617 | 0.84 | — | — | |
| SCHEMBL21933618 | 0.84 | — | — | |
| SCHEMBL10202604 | 0.84 | — | — | |
| SCHEMBL11625556 | 0.82 | CA1 (0.33) | CA1CA2ACHECA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| EP-0262388-B1 | DERIVATIVES OF 2-TERT.-BUTYL-4-METHYL-CYCLOHEXANOL, THEIR PREPARATION AND USE AS FRAGRANCE COMPOUNDS | BASF Aktiengesellschaft (DE) | 1992-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179100-A1 | Protected monomers | PCNA, POLN, PARP1 | CA1 3859/4885CA2 3785/4885ACHE 4691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.